Distributor Update December 2022

NZX/ASX Announcement
19 December 2022
Distributor Update
Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU)
(‘TruScreen’ or ‘the Company), is pleased to provide this update on Distributor progress in November/
December 2022.
Poland
TruScreen has recently been recognised and awarded the Quality and Innovation Mark by the Polish
Medical University of Lodz. Lodz is the fourth largest city in Poland. The Polish University of
Technology, Lodz has also delivered a positive technical opinion on the TruScreen cervical cancer
screening device, led by Dr Anna Lipert. TruScreen is currently in discussion with a private network
of medical clinics, with 26 gynaecologists, to roll out the TruScreen cervical cancer screening device
to these centres.



Quality and Innovation Mark – Polish University of Lodz
II Fall Congress Academy of Gynaecology and
Obstetrics, Poland 11-14 October 2022


Zimbabwe
The TruScreen cervical cancer screening roll out by National Aids Council (NAC) in Zimbabwe
continues to make excellent progress. There has been a significant uptake following the ongoing
outreach programme by the NAC. The target of this phase is to reach 10,000 women in the Masvingo
province by the end of January 2023. The sixteen TruScreen devices in operation throughout the
region screened an average of 171 women per device in November with 376 per device being the
highest recorded to date.
TruScreen has recently submitted a tender for the supply of a further 10,800 SUS (Single Use Sensor)
which it is expected will be supplied in early 2023.

Vietnam
A TruScreen seminar hosted by Tu Du Hospital, the most influential gynaecological hospital in South
Vietnam, was held on 13 December and received substantial interest and positive feedback on the
performance of TruScreen. The seminar was attended by more than 100 doctors.
Dr Jerry Tan, General Manager Commercial, has recently completed a 7 day visit to Vietnam,
attending the Tu Du seminar, and participating in a charity project in the Central Highlands funded
by the distributor Gorton Health Services (GHS), which screened 1,000 local women. This initiative
received strong support and acclaim from the local government and opened the door for TruScreen
to enter a region with a population of nearly 6 million. During the visit, Dr. Tan met with Key Opinion
Leaders and officials from the various hospitals to provide further training and assistance to our local
distributor.
Vietnam has placed an order for 8 devices and 1,800 SUS which will be supplied in early 2023, to be
installed in 8 hospitals with screenings expected to commence in Q1 2023.
Russia/Kazakhstan
TruScreen’s Russia distributor JSC IMSystems has extended its presence to Kazakhstan.
Kazakhstan has a population of 18 million spread over an area of 2.7 million square kilometres (the
9
th
largest country in the world).
TruScreen has recently received an order for 5 TruScreen devices and 6,120 SUS which will
accelerate cervical cancer screening programmes in Russia and surrounding Central Asian countries.
Most doctors and clinicians in Kazakhstan, Kyrgyzstan, Armenia, and other Central Asian nations are
trained in Russia.

This announcement has been approved by the Board.

For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com



Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au

About TruScreen:


TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical
tissue in real-time via measurements of the low level of optical and electrical stimuli.
TruScreen’s technology enables cervical screening, without the need for sampling and processing of
biological tissues, avoiding failed samples, missed follow-up and discomfort, and negating the need
for costly, specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen ® Ultra, is registered as a primary screening tool for cervical cancer
screening.
The device is EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and
COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Zimbabwe, Israel, Ukraine,
and the Philippines, among others and has active distribution agreements in 23 countries. It i s also
National Medical Products Administration approved for sale in China. In 2021, TruScreen established
a manufacturing facility in China for devices marketed and sold in China.
To date, over 170,000* examinations have been performed with the TruScreen device and over 200
devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi
Arabia. TruScreen’s vision is “A world without the cervical cancer”.
To learn more, please visit: www.truscreen.com/.
*Based on Single Disposable Sheath sales.